SEC Form 4 · accession 0000914190-15-000266
REGENERX BIOPHARMACEUTICALS INC · RGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Allan L Goldstein
Director
Period of report
Sep 29, 2014
Accepted (ET)
Jul 2, 2015 · 4:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000707511
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 16, 2015 | G | 125,000 | $0.00 | D | 931,743 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Convertible Promissory Note (right to buy) | $0.15 | Sep 29, 2014 | D | — | D | Oct 19, 2012 | Oct 19, 2014 | Common Stock | — | 0 | D |
| Convertible Promissory Note (right to buy) | $0.15 | Sep 29, 2014 | A | — | A | Oct 19, 2012 | Oct 19, 2017 | Common Stock | — | — | D |
| Stock Option (right to buy)F2 | $0.36 | Jun 30, 2015 | A | 250,000 | A | — | Jun 30, 2022 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1The reported transaction resulted from the extension of the expiration date of the Convertible Promissory Note (the "Note") from October 19, 2014 to October 19, 2017. Such extension resulted in the deemed cancellation of the originally issued old Note and the issuance of a replacement Note. The Note was originally granted on October 19, 2012.
- F2The option vests in four equal annual installments beginning on June 30, 2015.
Remarks
On February 11, 2015, a Form 4 was filed for the reporting person that mistakenly reported the grant of a stock option that did not occur.